Revisiting Foam Sclerotherapy: Challenging the 7 mm Dogma
Haroun Gajraj, a Self-Employed Phlebologist, posted on LinkedIn.
”An excellent demonstration of the utility of Foam Sclerotherapy for Superficial Venous Disease.
Dogma (aka Guidelines) tells us that Foam is only useful for veins up to 7 mm.
Even then, long-term durability is widely thought to be inferior to endothermal ablation.
Thank you Massimo Pozza for sharing your expertise.
Those who get inferior results are not doing it right. Simple as that!”
Quoting Massimo Pozza‘s post:
” This is a very interesting case because the patient had a VGS dilation of about 2.4 cm at 30 cm from the crosse (average diameter calculated on the teaching of Dr. Sica of Paris) with this abnormal antero-medial collateral.
I treated the VGS with direct puncture to the middle lower III of the thigh with 1% R L/A 1/4 foam about 8cc and then I treated the coarse collateral with atxscl 0.5/0.7% foam at the control after about 6 years the patient does not have recanalization of either the VGS or the coarse collateral and I limited myself to the treatment of some small collateral legs.
This is to highlight the
The fact is that very often it is enough to use delicate concentrations to have excellent results and that I prefer to use more aggressive concentrations depending on the patient’s response, which is different from person to person.
I always use Nadiax 3 nanoemulsion cream before and after the treatment and in this case elastocontension 35 mmHg for 7 days.”
” 
Stay updated with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry